This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the preliminary efficacy.
Subjects with ability to understand and voluntarily agree to participate by giving written informed consent for the study.
Patients with unresectable recurrent or metastatic solid tumors.
There is at least one lesion that could be measured.
An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
Patients with known active central nervous system (CNS) metastases.
Subjects who had other malignancy in five years before the first dose.
Patients with tumor-related pain that can not be controlled as determined.
Patients with serious cardiovascular and cerebrovascular diseases.